#EHA2024: Longer-term follow-up, patient outcomes, and real-world findings in multiple myeloma

To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Congress, we have collated our social media coverage. Catch up with our live social media relating to longer-term follow-up, patient outcomes and real-world findings in multiple myeloma here.

CONGRESS | POSTER | #EHA2024 | Julia Mersi presented findings on the spectrum and duration of infectious complications in patients treated with BCMA- and GPRC5D-targeted immunotherapies in MM, N=137. Different patterns of frequency and duration were observed. #mmsm #myeloma… pic.twitter.com/FjmxGP2qjZ

— Multiple Myeloma Hub (@MM_Hub) June 17, 2024

CONGRESS | POSTER | #EHA2024 | Katarina Uttervall discusses longer-term follow-up of patients with RRMM receiving prophylactic tocilizumab (n=24) for reduction of CRS in the phase I/II MAJESTEC-1 study. Prophylactic tocilizumab reduced Grade 1/2 CRS from 72.1 to 25%. #mmsm… pic.twitter.com/xPkoumpkNL

— Multiple Myeloma Hub (@MM_Hub) June 17, 2024

CONGRESS | POSTER | #EHA2024 | Mohamad Mohty @Mohty_EBMT shares long-term survival outcomes from the phase II MagnetisMM-3 study of elranatamab in patients with RRMM, N=123. ORR remained at 61%, with median DoR not reached. #mmsm #myeloma #MedicalCongress pic.twitter.com/FDjz9FIgSb

— Multiple Myeloma Hub (@MM_Hub) June 17, 2024

CONGRESS | POSTER | #EHA2024 | Leo Rasche @RascheLeo shares long-term efficacy and safety results from the phase I/II MONUMENTAL-1 study of talquetamab (TAL) in patients with RRMM, N=375. ORR ≥70% in TCR-naïve and 67% in prior TCR. #mmsm #myeloma #MedicalCongress pic.twitter.com/n6udlYNyn3

— Multiple Myeloma Hub (@MM_Hub) June 17, 2024

CONGRESS | POSTER | #EHA2024 | Sharlene Dong @sharlenedong discusses real-world carfilzomib (K) prescribing patterns and outcomes for patients with RRMM, N=2420. Once-weekly K dosing is now SoC; higher doses/frequencies were not associated with improved outcomes vs weekly K… pic.twitter.com/fLC5636zCO

— Multiple Myeloma Hub (@MM_Hub) June 17, 2024

CONGRESS | POSTER | #EHA2024 | Saad Usmani @szusmani @MSKCancerCenter shares findings from a real-world schedule de-escalation of teclistamab (TEC) in patients with RRMM, N=86. Despite a high-risk patient population, TEC demonstrated a 61% ORR, comparable to MajesTEC-1. #mmsm… pic.twitter.com/d7I5iDRSf1

— Multiple Myeloma Hub (@MM_Hub) June 17, 2024

CONGRESS #EHA2024 | Presidential Session | @BrunoPaiva_UNA @ClinicaNavarra @CIMA_unav @idisnanavarra provides an insightful discussion on innovative tools for disease monitoring in #MultipleMyeloma. They discuss current disease monitoring strategies and potential future… pic.twitter.com/bQpDHiVImE

— Multiple Myeloma Hub (@MM_Hub) June 16, 2024

CONGRESS #EHA2024 | Sarah Cayla, @univ_paris_cite highlights an analysis of outcomes of patients with R/R MM following early progression after ide-cel therapy using the DESCAR-T database. Patients who relapsed after ide-cel had poor outcomes, even with the use of bispecific… pic.twitter.com/BRugytJne0

— Multiple Myeloma Hub (@MM_Hub) June 16, 2024

CONGRESS #EHA2024 | Philippe Moreau, @CHUnantes presents long-term outcomes from the phase III CASSIOPEIA trial of D-VTd followed by DARA maintenance in transplant-eligible patients with NDMM. D-VTd induction and consolidation plus DARA maintenance resulted in the most pronounced… pic.twitter.com/WoZ4aEgQBW

— Multiple Myeloma Hub (@MM_Hub) June 15, 2024